DrugPatentWatch Basic Plan

thinkBiotech LLC, May 2013

DrugPatentWatch provides information on drug patents and their expirations. Datasets include Paragraph IV challenges, tentative approval (an indicator of generic entry), patent claim types, annual sales, patent expirations, failure to pay maintenance fees, ex parte and inter partes reexamination, interference, and disclaimers. Complete details are provided for all FDA-approved small molecule drugs. Annual sales information is available for top-selling drugs. This value-added information supports the critical business functions of patent agents and attorneys, pharmaceutical companies, wholesalers, healthcare payers, and investors.

The Basic Plan provides comprehensive information on all FDA-approved pharmaceutical drugs - discontinued and active, with and without patent protection or other forms of market exclusivity.

The basic plan is simpler than the Premium Plan and Ultimate Plan, lacking the rich graphs, historical archives, sales data, and some of the more powerful search functions. Information on failure to pay patent maintenance fees, reexaminations, interferences, disclaimers, Paragraph IV challenges, and advanced search functions are also not included in the Basic Plan.

The Basic Plan is designed to answer the following questions:

- Which patents cover specific pharmaceutical drugs?
- When do key pharmaceutical drug patents expire?
- Which FDA market exclusivities protect drugs?

Database includes:

Impending patent expirations
Patent expiration date
Patent title and abstract
Pediatric exclusivity extensions

Search by applicant name
Search by approval date
Search by branded name
Search by generic name
Search by NDA Number
Search by patent number

Regulatory exclusivity
Use codes

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Also available

• DrugPatentWatch Premium Plan
• DrugPatentWatch Ultimate Plan

Customers who bought this item also bought

• PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2012/2013
• Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs
• Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs 2010
• U.S. Healthcare Reform: Impact on the Pharmaceutical Industry
• Risk Sharing and Innovative Contracting with CROs
• The Neurotechnology Industry 2012 Report
• Pediatric Drug Delivery
• Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens
• The 111th U.S. Congress Tackles Healthcare Reform and the Pharmaceutical Industry
• Japan: Pricing, Reimbursement and Regulatory Update